In 2023, Paul Lonergan embarked on a lengthy quest to identify the root cause of his persistent throat discomfort. Following numerous consultations with medical professionals, the Toronto resident received a startling revelation: he had a sizable tumor located at the base of his tongue.
Realizing the daunting challenge ahead, the 68-year-old braced himself for the battle. Lonergan underwent a grueling seven-week regimen of radiation therapy and chemotherapy, enduring multiple intensive care unit visits to eradicate all traces of his tumor.
However, uncertainty lingered over whether his cancer had been completely eradicated. Participating in a clinical trial facilitated by his healthcare team, Lonergan underwent a “liquid biopsy” procedure to ascertain the status of his condition. This innovative method of cancer detection utilizes simple blood tests to detect minuscule amounts of tumor DNA undetectable through conventional scans and examinations. Results revealed residual tumor fragments in Lonergan’s bloodstream, hinting at the potential resurgence of his previously treated tongue cancer.
Subsequently, Lonergan was offered experimental immunotherapy and subsequent liquid biopsies confirmed his cancer-free status. Access to this evolving cancer monitoring technique remains limited for most Canadians, primarily restricted to clinical trials and costly private facilities. Nonetheless, optimism is on the rise for broader accessibility in the future.
Dr. Ramy Saleh, a cancer specialist and medical oncologist at McGill University Health Centre in Montreal, expressed enthusiasm for the transformative impact of this approach on disease surveillance. Describing liquid biopsies as a potential game-changer in disease recurrence monitoring, Saleh highlighted the technology’s revolutionary capabilities.
In a groundbreaking initiative, a research team based in Toronto is launching an extensive, multi-year project to integrate this emerging technology into standard patient care practices. The primary objective is to enhance the safeguarding of cancer survivors against potential disease relapses while sparing them from invasive and costly treatments.
Under the leadership of scientists from the University Health Network (UHN) in Toronto, a 5-year clinical trial has been initiated. The study aims to offer liquid biopsies to over 7,000 patients who have undergone conventional curative cancer treatments across various types of cancer. Dr. Lillian Siu, the lead investigator, outlined the study’s goal of detecting circulating tumor DNA indicative of potential cancer recurrence.
Dubbed as SHERLOCK, the project emphasizes early detection of cancer through blood tests before clinical or imaging evidence emerges. The ultimate objective is to enable timely intervention and enhance treatment outcomes for patients.
Despite the promising prospects, challenges lie ahead in integrating liquid biopsies into routine care due to associated costs. Saleh underscored the necessity of balancing the financial aspects with patient access to this innovative technology, emphasizing its potential to revolutionize cancer care.
As the UHN trial progresses towards its conclusion in 2031, Siu remains optimistic about the insights it will provide into the widespread implementation of liquid biopsies in cancer management. The ultimate aim is for this testing to become a standard practice, benefiting a significant number of patients across Canada and globally.
